Drug Eluting Stents Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMMD1116 | Last Updated On: Oct 26 2022 | Available Formats

> Global Drug Eluting Stents Market Expected to reach a high CAGR of 5.5% By 2029: DataM Intelligence

Drug Eluting Stents Market is segmented By Coating (Polymer-based coating stents (Non-biodegradable polymer, Biodegradable polymer), Polymer-free coating stents), By Application (Coronary Artery Diseases, Peripheral Artery Disease), By End-user (Hospitals, Ambulatory Surgical Centers, Cardiac Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Drug Eluting Stents Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.5% during the forecast period (2022-2029).      

Drug Eluting Stents Market



Market CAGR


Segments Covered

By Coating, By Application, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Download free sample click here

Stents are small mesh tubes inserted to open arteries after angioplasty (percutaneous coronary intervention). A drug-eluting stent (DES) is a peripheral or coronary stent in narrowed, diseased coronary or peripheral arteries. It gradually releases a drug to prevent fibrosis that, when coupled with clots, could block the stented artery.

Market Dynamics

The global drug eluting stents market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of cardiovascular disease, increasing drug approvals, and rising patient healthcare expenditure.

An increasing number of surgical procedures across the globe drives the market growth     

The global drug-eluting stents market is driven by increasing incidences of cardiovascular diseases (CVD), the growing old population, and a rising number of government initiatives like favorable reimbursement policies. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70.

As per the article published in StarPearls, in July 2022, dual drug-eluting stents DDES carry two therapeutic agents to combine their mechanism of action, for instance, antiproliferative and additional anti-thrombotic effects. The coating modification allows the time-controlled release of the drugs to target the different timing of bio-response to stent implantation.

Moreover, technological advancements, rising R&D and the growing demand for minimally invasive surgery are anticipated to boost the market as minimally invasive treatments let patients heal faster and avoid significant complications in procedures like open-heart surgery.

The risks associated with drug-eluting stents will hamper the growth of the market  

However, angioplasty is a less intrusive way to open clogged arteries than bypass surgery, but the procedure still carries some risks. Re-narrowing of the patient's artery, when angioplasty is combined with drug-eluting stent placement, there's a small risk that the treated artery will become clogged again. The risk of re-narrowing the artery is higher when bare-metal stents are employed. In addition, the rare risk includes heart attack, coronary artery damage, kidney problems and stroke.

COVID-19 Impact Analysis

The pandemic coronavirus disease 2019 has posed a significant threat to people’s health worldwide, with specific importance for patients with underlying heart diseases. Heart patients are more susceptible to coronavirus infection. It raises the threat to the heart patient.

In addition, as per the Clinical Case Reports, in May 2022, drug-eluting stents and dual antiplatelet therapy are vital preventive measures. An alarming phenomenon observed recently is that the incidence of stent thrombosis can be up to ten times higher in COVID-19 patients than in non-COVID-19 patients.

On the other hand, major players are focusing on getting FDA approval for new products and launching new products during a pandemic. For instance, in February 2020, the United States FDA continued to acknowledge a possible mortality risk with paclitaxel-coated balloons and stents intended to treat new or recurring atherosclerotic lesions in the femoropopliteal artery. The FDA is still monitoring the safety of Placitaxel stents in PAD.

Segment Analysis

The polymer-based coating stents segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)        

The polymer-based coating stents segment accounts for the largest market share. Minimally invasive cardiovascular stents can be implanted into impaired vessels to supply mechanical support to the blood vessel wall, substantially improving revascularization's quality. Applying a bare-metal stent in clinical practice has enhanced the efficacy of the percutaneous coronary intervention.

As per the article published in Materials Today Bio in 2022, novel technologies for base neo-intimal length also provide new insights into the development of cardiovascular scaffolds. For example, bioresorbable electronic stents, including biosensors, can convey information about the internal status of stents in real time. 3D printing technologies allow designing BRS, which is specifically tailored to each patient for better clinical outcomes

In addition, the biodegradable polymeric stents possess good biocompatibility as giant cells and leukocytes could remove their degradation debris, thus avoiding severe chronic inflammatory response. For instance, histological analyses of BDPS in animal experiments showed reduced inflammatory responses.

Moreover, polymers are the reservoir from which the drug is released in a controlled way towards the arterial wall. XIENCE (Abbott) and Resolute Onyx (Medtronic) stents have permanent polymers but improved biocompatibility. The XIENCE polymer is highly fluorinated, which minimizes adhesion and platelet activation increasing the safety profile. The Onyx stent utilizes Biolinx, a mixture of polymers with hydrophilic capabilities that make it biocompatible and hydrophobic for a prolonged and uniform drug release.

Geographical Analysis

North America region holds the largest market share of the global Drug Eluting Stents market

North America dominates the market for drug-eluting stents and is expected to show a similar trend over the forecast period. The market is driven by factors such as the increasing prevalence of cardiovascular disease, the rising geriatric population, advanced healthcare infrastructure and key regional players. 

As per America’s Health Rankings Senior Report 2021, More than 54 million adults ages 65 and older live in the United States. The United States Census Bureau accounts for about 16.5% of the nation’s population. The number of older adults in the U.S. is growing; by 2050, the total number of adults ages 65 and older is expected to rise to an estimated 85.7 million, roughly 20% of the overall U.S. population. There is a growing need to improve the health of older Americans. The increasing geriatric population and increasing prevalence of cardiovascular disease drive the market in the North American region.

In addition, the market players are focusing on the approval of the new products. For instance, in June 2021, Abbott received approval from the United States FDA for its XIENCE family of drug-eluting stents for one month (as short as 28 days) for dual-antiplatelet therapy labeling for high bleeding risk (HBR) patients in the United States region.

Competitive Landscape

The drug-eluting stents market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Biotronik Inc., Johnson & Johnson, MicroPort Scientific Corporation, Cook Medical Inc., Stentys S.A., Biosensors International Group, Terumo Corp., Lepu Medical Technology Co., Ltd, and Meril Life Science, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the drug-eluting stents market globally. 

For instance, 

  • In February 2020, BIOTRONIK announced CE Mark certification for the Orsiro Mission drug-eluting stent (DES) system. The Orsiro DES offers higher deliverability than other contemporary stents. Orsiro DES is available in CE Mark countries. 

Boston Scientific Corporation


Boston Scientific is a multinational biotechnology company founded in 1979 and headquartered in the United States. It provides advanced solutions to fight against PAD by boldly innovating with next-generation, drug-eluting technology.

Product Portfolio:

Eluvia Drug-Eluting Vascular Stent System:    It is designed with sustained release to reach the restenotic process of the SFA and has proved superior primary patency at 1-Year against bare metal stents in EMINENT2 and Zilver PTX in IMPERIAL3. Eluvia DES delivers excellent results.

The global drug eluting stents market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.  

Trending Topics

Polycystic Kidney Disease Market

Intra-Dialytic Hypotension (IDH) Market

Hyperhidrosis Treatment Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!